← Back to Search

Behavioural Intervention

Amblyopia therapy with Curesight outside FDA limited ranges for Lazy Eye (ABCDCS Trial)

N/A
Recruiting
Led By Robert W Arnold, MD
Research Sponsored by Alaska Blind Child Discovery
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2-6 months
Awards & highlights

ABCDCS Trial Summary

This trial tests a device to treat amblyopia, a vision problem, in patients at home. Device is used 1.5 hours/day, 6 days/week for 3-6 months to determine if it works.

Who is the study for?
This trial is for individuals with amblyopia, commonly known as 'lazy eye,' who are not part of the Novasight FDA study and have the potential to improve their vision. Participants must have home WiFi access and should not have any neurological or ocular conditions that would prevent visual improvement.Check my eligibility
What is being tested?
The trial is testing a device called Curesight, which patients use at home for 1.5 hours daily, six days a week over 3-6 months. The treatment involves eye-tracking technology aimed at improving visual acuity and stereo vision in people with lazy eye.See study design
What are the potential side effects?
While specific side effects are not detailed here, treatments involving visual exercises typically may cause temporary eyestrain or headaches due to the intensive focus required during sessions.

ABCDCS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2-6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2-6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Visual acuity
Secondary outcome measures
stereopsis

ABCDCS Trial Design

1Treatment groups
Experimental Treatment
Group I: Amblyopia therapy with Curesight outside FDA limited rangesExperimental Treatment1 Intervention
Severity of amblyopia and age range outside FDA study
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CureSight
2018
N/A
~50

Find a Location

Who is running the clinical trial?

Alaska Blind Child DiscoveryLead Sponsor
9 Previous Clinical Trials
6,202 Total Patients Enrolled
Robert W Arnold, MDPrincipal InvestigatorAlaska Blind Child Discovery
5 Previous Clinical Trials
4,961 Total Patients Enrolled
~11 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top